It doesn't seem to want to break out of the 4.80-5 range until some more news, but from a short term perspective I think a 4.80 buy and flip for quick profit seems reasonable at this point. The price action on this guy is completely controlled by MM's at this range
Ok - I've waited for the usual post-ASH drop. Told everyone, but everybody was rah rah buying INTO Ash, talking about technicals once it broke 6....really?? Where are they now?. Can pick up a little here and the nsome more as reality sets in that ARRY is years away from a marketable drug. Good pipeline, but this'll take patience. No hurry to buy. Little chunks on down days. And you'll get more down days...
I am here long, quite a few shares but I think honestly it's all coming down to the mek inhibitors.....the rest of the pipe are all long shots
sold into the close today at $4.98
looking for opinion of others. does this still have some gas left in it over $5? or will it pull back from here?
I think by mid 2015 you will be happy happy that you own this one ads, short term not so much. With this pipeline, and their partners, it is a good risk/reward investment. Like I stated else where, I am not so much banking on Arry, or their management, but on the heavy hitting partners pouring millions into ARRY phase studies. They will abandon a phase 2 in a NY minute, for several to go phase 3, ODDS are on our side. Patience here is everything.
There are over 60 phase trials on going??? So not sure your point on PROPER R&D. As far as marketing the company take a look at fund ownership. Those funds are not worried about the current share price but they are well aware of the potential with over 60 phase studies. How do you suggest that company FUND itself to move their pipeline forward? The ATM set up sucks for sure, but beats large secondaries. Not one of ARRY'S molecules has proven out in phase 3, to date. The best WAY this company can help the share holder, actually, the only way, is to have a successful or several successful phase 3 studies. This is a BUY and HOLD, big payoff or a complete bust. THE ODDS are heavily tilted toward big payoff. Not because of ARRY or their management, BUT their partners are some of the best on the planet. These partners are pouring 100's of millions into those phase studies. THEY would not do so unless PHASE 2 was THAT compelling.
In 18 months or less you will know one way or the other if Arry is a BUST or a grand slam. Management can not help the share price, phase study results can.
publicly traded biopharmaceutical company headquartered in San Diego, CA, with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX began dosing in its pivotal Phase 3 clinical study of MST-188 (purified poloxamer 188) in sickle cell disease in May. MSTX believes that it is currently the only company with a new molecular entity in a Phase 3 clinical trial for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented interest from strategic partners, acquisition oriented suitors, and financial investors." Mr. Silver continued, "MSTX plans to develop MST-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. The planned Phase 2 trial in ALI is scheduled to commence in the first quarter of 2014." Mr. Silver concludes, "MSTX anticipates that cash as of September 30, 2013 or $0.48/share, should be sufficient to fully fund all planned clinical trials."
not sure of a takeout but Amgen ( Kyprolis) as well as with Takeda (Velcade) would be crazy not to license 520. BTW Velcade is going off patent and its a $2 billion drug A buyer of . Array gets the pipeline to boot.
I see 10 to 12 bucks buy early summer maybe 15 to 20
As I said before, I was looking at this because of the asthma medicine. I waited a bit as I have learned that patience truly is virtue and got in yesterday. Thanks for all your diligence and I agree, this will be bought out within a couple years. I was a little concerned by the departure by a main guy about a month ago, but I see a lot of positives even if management has a few issues to sort out.
If you follow me , youll also see that I only buy companies that WILL be bought out. including ARRY and DNDN
Just could not imagine the Russell is heavily shorted and it took out Arrys progress. I am not complaining, just picked up some more a few minutes ago. Not worried about ARRY nearterm. They have cash and partners who can take the helms here./